NAD+ is the coenzyme that powers cellular energy production and DNA repair — and its decline with age is one of the most documented molecular hallmarks of aging. Injectable and IV NAD+ directly replenishes cellular NAD+ levels to activate sirtuins and PARPs.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme found in every living cell, essential for hundreds of metabolic reactions. It accepts and donates electrons in the mitochondrial electron transport chain, fueling ATP production, and serves as a substrate for sirtuins (NAD+-dependent longevity enzymes) and PARPs (DNA repair enzymes). NAD+ levels decline approximately 50% from young adulthood to old age, correlating with decreased mitochondrial function, reduced DNA repair capacity, impaired cellular stress response, and many hallmarks of metabolic aging. Injectable NAD+ bypasses the gut metabolism of oral precursors (NMN, NR) and directly delivers the active coenzyme to the bloodstream.
Mechanism of Action
NAD+ serves as an electron carrier in glycolysis and the TCA cycle, shuttling electrons to the mitochondrial electron transport chain for ATP synthesis. As a substrate for SIRT1 through SIRT7 (sirtuins), NAD+ enables the deacetylase activity that regulates gene expression, mitochondrial biogenesis, inflammation, and cellular repair. PARP enzymes consume NAD+ to add poly-ADP-ribose chains to DNA during repair of single-strand breaks — making NAD+ availability directly rate-limiting for DNA repair rate. CD38 (NAD hydrolase) increases with age and chronic inflammation, becoming a major consumer of NAD+ and a driver of NAD+ decline. Restoring NAD+ levels through supplementation or inhibition of CD38 is the mechanistic target of multiple longevity interventions.
Key Research
NAD+ research spans over two decades with foundational work by David Sinclair (Harvard), Johan Auwerx (EPFL), and Charles Brenner. Human clinical trials demonstrate NAD+ restoration via oral precursors (NMN, NR) safely raises blood NAD+ levels and improves metabolic markers. IV NAD+ clinics report rapid improvements in energy, mental clarity, and addiction recovery, though controlled trial data is limited for IV protocols specifically. NMN supplementation studies in older adults showed improvements in muscle strength and walking speed. Animal studies demonstrate NAD+ restoration reverses multiple aging hallmarks, extends healthy lifespan, and protects against metabolic and neurodegenerative disease.
500 mg–1 g IV infusion; 100–500 mg IM injection; 250–1,000 mg orally (NMN/NR)
Half-Life
IV: rapid replenishment, effect lasts 4–7 days; IM: similar
IV NAD+ is typically administered as a slow infusion of 500 mg to 1 g over 2–4 hours, once per week or biweekly, through clinical facilities. IM injection at 100–500 mg is more practical for at-home research use. Oral NAD+ precursors (NMN 500 mg, NR 300–500 mg) are the most practical for daily maintenance dosing. IV protocols are used for acute restoration or specific clinical contexts (addiction recovery, fatigue, neurological support). Combining with resveratrol (sirtuin activator) or apigenin (CD38 inhibitor) amplifies the NAD+ restoration effect.
NAD+ Restoration Protocol: 500 mg IV over 3 hours once weekly for 4–8 weeks, then 250 mg IM weekly for maintenance. Combine with oral NMN 500 mg daily between infusions. Longevity Stack: NAD+ IV + MOTS-c 5 mg SC 3x weekly + Epithalon pulse for comprehensive cellular energy and telomere support. Addiction Recovery Protocol: 500 mg–1 g IV daily for 10 days under clinical supervision for NAD+-based detox protocols.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
IV NAD+ infusions commonly cause transient side effects during infusion: chest tightness, nausea, flushing, headache, and general discomfort — typically dose and infusion-rate dependent. Slowing the infusion rate (over 3–4 hours rather than 1) significantly reduces these effects. IM injection causes injection site pain and warmth, which is common and manageable. Oral precursors (NMN, NR) are very well tolerated; mild flushing (from NR's niacin-related activity) may occur initially. NAD+ restoration may activate inflammatory pathways transiently as cellular repair processes are stimulated — a typically short-lived response. Monitor blood glucose and liver enzymes in individuals with diabetes or hepatic conditions.
Storage & Handling
Injectable NAD+ vials should be stored at 2–8°C, protected from light. Do not freeze liquid formulations. Lyophilized NAD+ powder: store at -20°C for long-term stability. Once dissolved, use within 24 hours for IV preparation or within 7 days for IM use. Oral supplements (NMN, NR): store at room temperature in a sealed, dark container away from moisture. NMN is hygroscopic — keep tightly sealed.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
